FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

Nur für Forschungszwecke. Vollständige Erklärung →

Peptidebibliothek

FDA-gegeregelter Komponente

Diese Komponente ist FDA-zertifiziert oder -reguliert. Das Kauf ohne gültige Rezept kann eine Verletzung des Bundesrechts sein. Stellen Sie alle rechtlichen Anforderungen in Ihrer Jurisdiktion sicher.

HCG

Human Chorionic Gonadotropin / Pregnyl / Novarel

Sexual Health

Human Chorionic Gonadotropin (HCG) is a glycoprotein hormone naturally produced during pregnancy that mimics luteinizing hormone (LH) activity at the Leydig cells. It is FDA-approved for the treatment of hypogonadism, cryptorchidism in pediatric patients, and as a fertility treatment to induce ovulation. In clinical practice, it is widely used alongside testosterone replacement therapy to maintain testicular function and intratesticular testosterone production.

Wirkmechanismus

Glycoprotein hormone that mimics luteinizing hormone (LH) action. In males, stimulates Leydig cells to produce testosterone. In females, triggers ovulation and supports corpus luteum progesterone production. Maintains testicular function during exogenous hormone use.

Forschungsprotokolle

Nur für Forschungszwecke. Keine medizinische Beratung.

Male research protocols use 250-500 IU 2-3 times weekly to maintain testicular function. Female protocols (fertility) use 5,000-10,000 IU to trigger ovulation. Intramuscular or subcutaneous injection.

Forschungsnotizen

Clinical Research Status

HCG holds longstanding FDA approval for multiple indications including male hypogonadism, prepubertal cryptorchidism, and female infertility (ovulation induction). It has been used clinically since the 1930s with an extensive safety database spanning decades. Compounded HCG was temporarily restricted by the FDA in 2020 under the Biologics Control Act, though branded pharmaceutical versions (Pregnyl, Novarel) remain available.

Key Published Findings

Studies demonstrate that HCG at doses of 500-1500 IU two to three times weekly maintains intratesticular testosterone levels and spermatogenesis during exogenous testosterone administration. Research confirms LH receptor activation by HCG stimulates both testosterone production and supports Sertoli cell function critical for sperm maturation. In fertility contexts, HCG triggers final oocyte maturation at doses of 5,000-10,000 IU as a surrogate LH surge.

Safety Profile

Common side effects include injection site pain, headache, and mood fluctuations related to hormonal changes. Prolonged use at high doses can cause Leydig cell desensitization, potentially reducing endogenous LH receptor sensitivity. Gynecomastia may occur due to downstream aromatization of increased testosterone, and rare cases of ovarian hyperstimulation syndrome occur in female fertility use.

Comparison to Related Compounds

Unlike gonadorelin which stimulates the pituitary to release LH, HCG acts directly at the gonadal level bypassing the hypothalamic-pituitary axis. This makes HCG effective even in patients with suppressed gonadotropin release from exogenous testosterone use. Compared to recombinant LH (Luveris), HCG has a longer half-life of approximately 24-36 hours and is significantly less expensive.

Community Observations

HCG is considered essential by many TRT practitioners for maintaining testicular size and preserving fertility potential during testosterone therapy. Typical protocols use 250-500 IU two to three times per week alongside testosterone, with some clinicians preferring every-other-day dosing. The 2020 regulatory changes affecting compounded HCG availability created significant disruption for patients relying on lower-cost compounded preparations.

Halbwertszeit

~24-36 hours

Rekonstitution

Bacteriostatic water (BAC) provided with kit

Lagerung

Lyophilisiert

Refrigerate 2-8C.

Rekonstituierter

Refrigerate 2-8C. Use within 30 days.

Rechtsstatus USA

FDA-approved (Rx only)

Auch bekannt als

Human Chorionic GonadotropinPregnylNovarel

Häufig gestellte Fragen

Was ist HCG?

Human Chorionic Gonadotropin (HCG) is a glycoprotein hormone naturally produced during pregnancy that mimics luteinizing hormone (LH) activity at the Leydig cells. It is FDA-approved for the treatment of hypogonadism, cryptorchidism in pediatric patients, and as a fertility treatment to induce ovulation. In clinical practice, it is widely used alongside testosterone replacement therapy to maintain testicular function and intratesticular testosterone production.

Wie wirkt HCG?

Glycoprotein hormone that mimics luteinizing hormone (LH) action. In males, stimulates Leydig cells to produce testosterone. In females, triggers ovulation and supports corpus luteum progesterone production. Maintains testicular function during exogenous hormone use.

Wie ist der regulatorische Status von HCG in den USA?

FDA-approved (Rx only)

Wie lang ist die Halbwertszeit von HCG?

~24-36 hours

Wie wird HCG noch genannt?

Human Chorionic Gonadotropin, Pregnyl, Novarel

Peptide Contacts bietet wissenschaftliche Zusammenfassungen für informationstechnische Zwecke an. Wir stellen keine Dokumentationen von Anbietern, keine Host- und keine Vertriebsdienstleistungen zur Verfügung und unterstützen keine Anbieter in irgendeiner Weise. Alle Zertifikate der Analyse, GMP-Zertifikate und Kommunikationen mit Anbietern müssen direkt vom Käufer angefordert und überprüft werden. Alles auf dieser Plattform stellt weder rechtliche, medizinische noch berufsmäßige Beratung dar. Nutzer sind allein verantwortlich für die Überprüfung der Anbieterzertifikate und das Gewährleisten des Einhaltens aller anwendbaren lokalen, zuständigen und federalen Gesetze beim Kauf von Forschungschemikalien. Die Nutzung dieser Plattform bedeutet die Annahme volles persönlichen Verantwortlichkeitsbewusstseins.

Ganze Erklärung lesen